Erik J. Stoops
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration.
Journal: Nature medicine
Published: November 18, 2025
Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].
Journal: The journal of prevention of Alzheimer's disease
Published: June 06, 2025
Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy.
Journal: NPJ Parkinson's disease
Published: March 29, 2025
Serum neuronal pentraxin 2 levels are associated with shorter survival in amyotrophic lateral sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: March 06, 2025
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: November 26, 2024
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: October 10, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.
Journal: Alzheimer's research & therapy
Published: September 13, 2024
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.
Journal: medRxiv : the preprint server for health sciences
Published: September 04, 2024
Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217.
Journal: Alzheimer's research & therapy
Published: August 13, 2024
Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy.
Journal: Alzheimer's research & therapy
Published: July 06, 2024
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Journal: Alzheimer's research & therapy
Published: November 29, 2023
Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET.
Journal: Brain communications
Published: November 17, 2023
Last Updated: 09/26/2026